• Home
  • News
  • CARBOGEN AMCIS announces a co-investment agreement of more than CHF 4 million with a long-standing Europe-based client

CARBOGEN AMCIS announces a co-investment agreement of more than CHF 4 million with a long-standing Europe-based client

BUBENDORF, Switzerland (27 Aug 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the signing of a co-investment agreement with one of its key European customers.

The agreement provides for additional process capabilities and capacities to facilitate the manufacture of the customer’s commercial product and is following a previous investment of CHF 6 million.

The recent co-investment totals CHF 4 million and will be dedicated to expanding capacities and supporting the market introduction of the key customer’s lead compound. The investment includes the additions to the CARBOGEN AMCIS Neuland site of a medium pressure chromatography column (200L), a preparative 20 cm HPLC system and short path distillation equipment.

“We are committed to providing our customers with the best technologies and this investment will allow our client to benefit from state-of-the-art equipment that enables expanded manufacturing capacity to commercialization scale-up, and getting a much-needed drug to patients,” said Stephan Fritschi, VP operations, CARBOGEN AMCIS.

This equipment set will be dedicated to the production of key intermediates for the customer’s pharmaceutical product. This agreement is following a previous CHF 6 million investment made in 2017 by the same customer for CARBOGEN AMCIS’ Neuland site.

The collaboration between the two companies spans more than 10 years and started as early as the project’s pre-clinical development stage. “We have supported our client from the early stages of pre-clinical development all the way through to routine commercial manufacture. We are proud to be part of our customer’s successful journey towards product commercialization and this co-investment is the latest milestone in our long-standing partnership,” said Pascal Villemagne, VP sales and marketing, CARBOGEN AMCIS.

CARBOGEN AMCIS’ Neuland site specializes in early phase development and rapid kg API supply to GMPs. Its strong analytical capabilities and crystallization lab can serve up numerous customers simultaneously. The recent chromatography equipment addition reinforces the extensive offerings available at this site.

The equipment is expected to be ready for production by Q1 2023.

****

CARBOGEN AMCIS (www.carbogen-amcis.com) is a leading service provider offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Our integrated services and innovative chemistry solutions support timely and safe drug development, allowing customers to better optimize available resources. CARBOGEN AMCIS is a wholly owned subsidiary of Dishman Carbogen Amcis Limited, Ahmedabad, India.

Dishman Carbogen Amcis Limited (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.